Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: pz who wrote (1399)	11/5/1999 3:35:00 AM
From: Street Walker	Read Replies (2) \| Respond to of 5582

VERY IMPORTANT Read this: biz.yahoo.com What word sticks out in my mind is.....the G... tactics The Second Clinicals are out in 1 week. ZICAM is SOLD OUT and stores are Re-ordering. The publication in Feb 2000 by the withdrawn journal would have little affect anyway because they were so slow in their peer review, the second clincials will have pre-empted them. * * * It was the fault of the Journal for not getting their job done faster and getting the results published BEFORE the second clinicals. Regards, S.W. PS: ------ for the true longs, Friday may present a buying opportunity as weaklings sell. Think of this, can you afford not owning shares before Monday? Kovel Fuller ---- what is next ??? We just finished the Trick or Treat, now we want the Treat. :-) kovelfuller.com -

To: pz who wrote (1399)	11/5/1999 7:53:00 AM
From: DanZ	Read Replies (2) \| Respond to of 5582

These two lines from the press release are most important. "According to Elaine Larson, editor of AJIC, the peer review process was in order and the manuscript was reviewed by experts in the field. It followed an accepted blind review process." Translation: The manner in which the study was conducted was proper and met our established policies and regulations. "However, based on the pre-release of data and related issues not in compliance with the established policies and copyright regulations of the Journal, the manuscript has been withdrawn from publication." Translation: We don't like the PR that resulted from the announcement. The bottom line is that the study is not at issue. The only thing that is at issue is that data was released before they published it. The only thing that isn't well understood right now is specifically what data was released that violated AJIC's policies. No matter what that data is, it is irrelevant to the efficacy or validity of the study itself. GumTech had a fidiciary reponsibility to tell shareholders that the study had been accepted for publication and most of the PR resulted from the media autonomously picking up on the press release. This changes absolutely nothing about the long term outlook for GumTech. They will still sell a lot of Zicam, nicotine gum is coming, a large dental gum contract is coming, and stock price will recover from the small hit that it might take today because nervous short term traders never intended to invest in this company anyway. There is still a large short interest in the stock and they know that they have lost in the long term. I believe that they will be buying today because this will be their last chance to get out of the stock before the second clinical results and nicotine joint venture are released. This isn't bad news when you think about it rationally and with a cool head.